Pharma Pulse: FDA Launches AEMS and the Rise of Direct-to-Employer Drug Purchasing

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let's get into today's headlines.

• The FDA has launched the Adverse Event Monitoring System, or AEMS. This unified platform replaces fragmented legacy databases, shifting safety surveillance from quarterly releases to real-time reporting. The transition is projected to save the agency approximately 120 million dollars over five years while providing "radical transparency" into the safety of regulated drugs and products.
• In other news, direct-to-employer drug purchasing is emerging as companies navigate high prescription benefit costs. New platforms allow employers to bypass traditional pharmacy benefit managers and purchase medications directly from manufacturers. Some suggest this trend could fundamentally restructure pharmaceutical distribution as employers seek relief from escalating brand-name drug expenditures.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.